Benzathine Cloxacillin Intramammary Infusion is the benzathine salt form of a semisynthetic beta-lactamase resistant penicillin antibiotic with antibacterial activity. Mainly used for the treatment of dairy cow mastitis.

The global Benzathine Cloxacillin Intramammary Infusion market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Benzathine Cloxacillin Intramammary Infusion volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Benzathine Cloxacillin Intramammary Infusion market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Benzathine Cloxacillin Intramammary Infusion Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
10ml：0.5g
250m1：12.5g

Segment by Application
Retail
Online Sale
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Boehringer Ingelheim
Zoetis
Merck
Fresenius Kabi iPSUM
Oriental Aolong
Huisheng Biological
Zhengzhou Bairui Animal Pharmaceutical Co., Ltd.
·